Our previous results showed that less than 10% of the clinically high risk breast cancer patients harbor BRCA1 and BRCA2 mutations, and importantly, nearly half of the mutations were recurrent mutations [2, 13]. The gene discussed is BRCA2; the disease is breast cancer.